Cytokine signaling - Regulation of the immune response in normal and critically ill states

Critical Care Medicine

Volumn 28, Issue 4 SUPPL., 2000, Pages

  Oberholzer, Andreas ^a   Oberholzer, Caroline ^a   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cell mediated immune response; Compensatory anti inflammatory response syndrome (CARS); Cytokine; Humeral immune response; Immunity; Systemic inflammatory response syndrome (SIRS)

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

CELLULAR IMMUNITY; CLONAL ANERGY; CRITICAL ILLNESS; CYTOKINE PRODUCTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TH2 CELL;

EID: 0034015682     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200004001-00002     Document Type: Review

References (79)

1. Fearon DT, Locksley RM: The instructive role of innate immunity in the acquired immune response. Science 1996; 272:50-53
2. Brown E, Atkinson JP, Fearon DT: Innate immunity: 50 ways to kill a microbe. Curr Opin Immunol 1994; 6:73-74
3. Wright SD, Ramos RA, Tobias PS, et al: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-1433
4. Klinman DM, Yi AK, Beaucage SL, et al: CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 1996; 93:2879-2883
5. Yi AK, Klinman DM, Martin TL, et al: Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol 1996; 157:5394-5402
6. Ulevitch RJ, Tobias PS: Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995; 13: 437-457
7. Holmskov U, Malhotra R, Sim RB, et al: Collectins: Collagenous C-type lectins of the innate immune defense system. Immunol Today 1994;15:67-74
8. Tracey KJ, Cerami A: Tumor necrosis factor: A pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45:491-503
9. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-2147
10. Dinarello CA: Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 1997; 112:321S-329S
11. Mosmann TR, Coffman RL: TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145-73
12. Lai WS, Carballo E, Strum JR, et al: Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 1999; 19:4311-4323
13. Kontoyiannis D, Pasparakis M, Pizarro TT, et al: Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies. Immunity 1999; 10: 387-398
14. Fantuzzi G, Dinarello CA: Interleukin-18 and interleukin-1 beta: Two cytokine substrates for ICE (caspase-1). J Clin Immunol 1999; 19:1-11
15. Perez C, Albert I, DeFay K, et al: A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990; 63:251-258
16. Black RA, Ruach CT, Kozlosky CJ, et al: A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells. Nature 1997; 385:729-732
17. Moss ML, Catherine-Jin SL, Milla ME, et al: Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor-α. Nature 1997; 385:733-736
18. Crowe PD, Walter BN, Mohler KM, et al: A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995; 181: 1205-1210
19. Mullberg J, Durie FH, Otten Evans C, et al: A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995; 155:5198-5205
20. Maskos K, Fernandez-Catalan C, Huber R, et al: Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. Proc Natl Acad Sci U S A 1998; 95:3408-3412
21. Colotta F, Re F, Muzio M, et al: Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 1993; 261: 472-475
22. Re F, Muzio M, De Rossi M, et al: The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: Characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med 1994; 179: 739-743
23. Sims J, Gayle M, Slack J, et al: Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci U S A 1993; 90:6155-6159
24. Giri JG, Wells J, Dower SK, et al: Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor regulation of IL-1 responses. J Immunol 1994; 153: 5802-5809
25. Pruitt JH, Welborn MB, Edwards PD, et al: Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. Blood 1996; 87:3282-3288
26. Economides AN, Ravetch JV, Yancopoulos GD, et al: Designer cytokines: targeting actions to cells of choice. Science 1995; 270: 1351-1353
27. Modur V, Li Y, Zimmerman GA, et al: Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Invest 1997; 100: 2752-2756
28. Tartaglia LA, Pennica D, Goeddel DV: Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993; 268:18542-18548
29. Aderka D, Engelmann H , Maor Y, et al: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175:323-329
30. Van Zee KJ, Kohno T, Fischer E , et al: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A 1992; 89: 4845-4849
31. Bogdan C, Vodovotz Y, Nathan C : Macrophage deactivation by interleukin 10. J Exp Med 1991; 174:1549-1555
32. Trinchieri G: Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13:251-276
33. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-454
34. Moldawer LL, Marano MA, Wei H, et al: Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989; 3:1637-1643
35. Moldawer LL, Lowry SF, Cerami A: Cachectin: its impact on metabolism and nutritional status. Annu Rev Nutr 1988; 8:585-609
36. Okusawa S, Gelfand JA, Ikejima T, et al: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81:1162-1172
37. Waage A, Espevik T: Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice. J Exp Med 1988; 167: 1987-1992
38. Kishimoto T, Akira S, Narazaki M, et al: Interleukin-6 family of cytokines and gp130. Blood 1995; 86:1243-1254
39. Hirano T, Akira S, Taga T, et al: Biological and clinical aspects of interleukin 6. Immunol Today 1990; 11:443-449
40. 2 in brain but not in peripheral blood mononuclear cells. Brain Res 1991; 562:199-206
41. Tilg H, Trehu E, Atkins MB, et al: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994; 83:113-118
42. Aderka D, Le JM, Vilcek J: IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989; 143:3517-3523
43. Barton BE, Jackson JV: Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun 1993; 61:1496-1499
44. Biron CA: Cytokines in the generation of immune responses to, and resolution of, virus infection. Curr Opin Immunol 1994; 6:530-538
45. Chehimi J, Trinchieri G: Interleukin-12: A bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J Clin Immunol 1994; 14:149-161
46. Dinarello CA: IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999; 103:11-24
47. Ghayur T, Banerjee S, Hugunin M, et al: Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 1997; 386: 619-623
48. Tsutsui H, Nakanishi K, Matsui K, et al: IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 1996; 157:3967-73
49. Dao T, Ohashi K, Kayano T, et al: Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 1996; 173:230-235
50. Moore KW, O'Garra A, de Waal Malefyt R, et al: Interleukin-10. Annu Rev Immunol 1993; 11:165-190
51. Smith KA: Interleukin-2. Curr Opin Immunol 1992; 4:271-276
52. Farrar MA, Schreiber RD: The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993; 11:571-611
53. Nakamura T, Kamogawa Y, Bottomly K, et al: Polarization of IL-4- and IFN-gamma-producing CD4+ T cells following activation of naive CD4+ T cells. J Immunol 1997; 158:1085-1094
54. Del Prete G, Maggi E, Romagnani S: Human Th1 and Th2 cells: Functional properties, mechanisms of regulation, and role in disease. Lab Invest 1994; 70:299-306
55. Ertel W, Keel M, Neidhardt R, et al: Inhibition of the defense system stimulating interleukin-12 interferon-gamma pathway during critical Illness. Blood 1997; 89:1612-1620
56. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24:1125-1128
57. Fong Y, Tracey KJ, Moldawer LL, et al: Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989; 170:1627-33
58. Hesse DG, Tracey KJ, Fong Y, et al: Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166:147-153
59. Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1:355-357
60. Waage A, Brandtzaeg P, Halstensen A, et al: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989; 169:333-338
61. Marano MA, Fong Y, Moldawer LL, et al: Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet 1990; 170:32-38
62. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-778
63. Drost AC, Burleson DG, Cioffi WG Jr, et al: Plasma cytokines following thermal injury and their relationship with patient mortality, burn size, and time postburn. J Trauma 1993; 35:335-339
64. Martin C, Boisson C, Haccoun M, et al: Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 1997; 25:1813-1819
65. Walley KR, Lukacs NW, Standiford TJ, et al: Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 1996; 64:4733-4738
66. Rogy MA, Coyle SM, Oldenburg HS, et al: Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg 1994; 78:132-138
67. Neidhardt R, Keel M, Steckholzer U, et al: Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma 1997; 42:863-870
68. Sherry RM, Cue JI, Goddard JK, et al: Interleukin-10 is associated with the development of sepsis in trauma patients. J Trauma 1996; 40:613-616
69. Lyons A, Kelly JL, Rodrick ML, et al: Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. Ann Surg 1997; 226:450-458
70. Ayala A, Perrin MM, Kisala JM, et al: Polymicrobial sepsis selectively activates peritoneal but not alveolar macrophages to release inflammatory mediators (interleukins-1 and -6 and tumor necrosis factor). Circ Shock 1992; 36:191-199
71. Ayala A, Perrin MM, Wang P, et al: Sepsis induces an early increased spontaneous release of hepatocellular stimulatory factor (interleukin-6) by Kupffer cells in both endotoxin tolerant and intolerant mice. J Surg Res 1992; 52:635-641
72. Ertel W, Kremer JP, Kenney J, et al: Down-regulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995; 85:1341-1347
73. O'Sullivan ST, Lederer JA, Horgan AF, et al: Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg 1995; 222:482-490
74. Wichmann MW, Ayala A, Chaudry IH: Severe depression of host immune functions following closed-bone fracture, soft-tissue trauma, and hemorrhagic shock. Crit Care Med 1998; 26:1372-1378
75. McCarter MD, Mack VE, Daly JM, et al: Trauma-induced alterations in macrophage function. Surgery 1998; 123:96-101
76. Volk HD, Reinke P, Krausch D, et al: Monocyte deactivation - Rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996; 22(Suppl 4):S474-S481
77. Fiorentino DF, Zlotnik A, Vieira P, et al: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146:3444-3451
78. Docke WD, Randow F, Syrbe U, et al: Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nature Med 1997; 3:678-681
79. Kox WJ, Bone RC, Krausch D, et al: Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: Proof of principle. Arch Intern Med 1997; 157:389-393